The *p53* tumor suppressor pathway is inactivated in approximately 50% of human cancers (www-p53.iarc.fr). The loss of p53 function in tumor cells allows increased proliferation, the inhibition of apoptosis, and cell metabolism switching, providing advantageous signals for tumor cell survival[@b1],[@b2]. Tumor cells have multiple mechanisms for disrupting p53 activity. Missense mutations in particular account for 80% of the alterations at the *p53* locus[@b2]. In addition, several negative regulators of p53 are overexpressed in many tumors of diverse origins[@b3]--[@b8]. Thus, increased levels of p53 inhibitors in tumor cells are other mechanisms that inhibit p53 function in human cancer. In particular, Mdm2 can inhibit p53 through its p53-binding domain and its carboxyl terminal ring finger domain, which is an E3 ubiquitin ligase of p53. Mdm4, a homolog of Mdm2, also inhibits p53 activity by binding to the transcriptional activation domain of p53. The importance of Mdm2 and Mdm4 in the inhibition of p53 has been shown with several knockout, knockin, and overexpressing transgenic mouse models *in vivo*. Studies from these mouse models have suggested that blocking the interaction of Mdm2 and/or Mdm4 with p53 could be a potential therapeutic strategy for cancer patients with wild-type *p53* alleles. Several Mdm2 inhibitors have been published and are undergoing clinical trials[@b9]--[@b11]. Strategies to block p53 and Mdm4 interaction are also under intensive investigation[@b12],[@b13].

Mouse Models of *Mdm2* and *Mdm4* Knockout {#s2}
==========================================

The *Mdm2-*knockout mouse is the first mouse model of negative regulators of p53. Loss of *Mdm2* leads to embryonic lethality due to excess apoptosis, which is completely rescued by concomitant deletion of *p53* ([Table 1](#cjc-32-07-371-t01){ref-type="table"}). This demonstrates that p53 activity is strictly repressed by Mdm2 during the developmental stages[@b14],[@b15]. The role of Mdm2 in the later stages of the mouse lifespan has also been investigated in two other mouse models. One mouse model contains a hypomorphic *Mdm2* allele, which only expresses approximately 30% of the wild-type *Mdm2* allele due to the insertion of a puromycin selection cassette in the *Mdm2* locus at intron 6. The mice with this hypomorphic allele show decreased lymphoid cells, increased radiosensitivity, and increased apoptosis in both lymphocytes and epithelial cells[@b16]. Another mouse model used to investigate the function of Mdm2 after birth is the *Mdm2-*knockout mouse with a *p53* hypomorphic *R172P* allele background. Because *p53R172P* only modestly induces *p53*-mediated cell cycle arrest, it rescues the embryonic lethality of the *Mdm2* null allele[@b17]. In this study, the loss of *Mdm2* caused neonatal death due to cell cycle arrest in multiple proliferating tissues, including the bone marrow and cerebellum. Although different tissues are affected by *Mdm2* reduction or deletion, both models demonstrate that Mdm2 inhibition of p53 is required for embryogenesis, after birth, and in adulthood.

###### Genetic mouse models of *Mdm2* and *Mdm4*

  Mouse model             Genotype                                                                                                                Phenotype                                                                                                           Reference(s)
  ------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  *Mdm2*                *Mdm2* null                                                                                                 Embryonic lethal around implantation                                                                                             [@b14],[@b15]
                     *Mdm2^Puro/Δ7−12^*                                                             Smaller mice, increased apoptosis in lymphocytes and epithelial cells, and increased radiosensitivity                                                                [@b16]
                 *p53^515C/515C^Mdm2^−/−^*                                  Mice die within 2 weeks after birth due to *p53*-dependent cell cycle arrest. Severe impairment in postnatal hematopoiesis and cerebellar development                                        [@b17]
                 *Mdm2^−/−^, p53^ERKI\ /−^*                Mice die shortly after p53 restoration with defects in multiple radiosensitive tissues; other radio-insensitive tissues, such as the lung, kidney, brain, and liver, are not affected.                        [@b18]
                      *Mdm2* transgene                                                                     Mice are predisposed to spontaneous tumor formation with a high incidence of sarcomas.                                                                        [@b40]
  Mdm4                  *Mdm4* null                                                                                          Embryonic lethal at 9.5-11.5 dpc (day post coitum)                                                                                   [@b19],[@b20],[@b21]
                  *Mdm4^−/−^,p53^KI\ /−^*                                                                                          Minor defects in radiosensitive tissues                                                                                               [@b22]
                        *Mdm4^Δing^*                                                                                                       Early embryonic lethal                                                                                                        [@b33]
                       *Mdm4^C462A^*                                                                                                       Early embryonic lethal                                                                                                        [@b34]
                  *Mdm4^Tg1^, Mdm4^Tg15^*                                                                Spontaneous tumorigenesis and accelerated tumorigenesis with *p53* heterozygous background                                                                      [@b41]
                    *ROSA26-pCAGG-Mdm4*       Mice with the *Mdm4* homozygous transgene die during embryogenesis, yet mice with the heterozygous *Mdm4* transgene are viable and not prone to spontaneous, radiation-induced or Eµ-myc-induced tumor formation.          [@b42]

To further investigate the role of *Mdm2* in adult tissues, Evan\'s lab used the tamoxifen-inducible *p53ER^TAM^* allele to restore p53 activity in the *Mdm2^−/−^, p53^KI/−^* mice. This mouse model further confirmed the requirement of the Mdm2 protein to inhibit p53 activity in the adult stage, and that the phenotypes were more severe than 30% of the *Mdm2* hypomorphic allele. The mouse died shortly after the restoration of p53 activity and had defects in multiple radiosensitive tissues. However, some classical radio-insensitive tissues, such as the lungs, kidneys, brain, and liver, were not affected by the restoration of p53 activity[@b18], indicating that the effects of Mdm2 inhibition are tissue-specific. This tissue specificity may be due to the different levels of endogenous p53 that can be restored. Therefore, it will be interesting to compare the endogenous levels of p53 in radiosensitive and -insensitive tissues.

More recently, two different strategies have been used to target the *Mdm4* locus. Using the viral gene trap technique, *Mdm4* transcription was blocked, and the mouse died around E10.5 to E11.5 dpc (day post coitum)[@b19],[@b20]. Another mouse model of the *Mdm4* conventional knockout led to *p53*-dependent embryonic lethality earlier than E9.5 dpc[@b21]. These studies show that the loss of *Mdm4* induces *p53*-dependent cell cycle arrest and apoptosis in different tissues, demonstrating that *Mdm4* is a non-redundant *p53* inhibitor of *Mdm2 in vivo*.

To examine the role of *Mdm4* in the adult stages, p53 activity was restored in the *Mdm4^−/−^, p53^KI/−^* mice. Although these mutant mice have only shown minor defects in radiosensitive tissues such as the spleen, thymus, and intestines, the mice remained normal and healthy[@b22]. This observation is consistent with previous reports suggesting that Mdm2 is a more potent inhibitor of p53 than Mdm4. However, there are caveats to these restoration strategies: 1) the efficiency of different tissues taking metabolized tamoxifen may vary; and 2) the mice start with only one allele of *p53* to be restored.

Based on the results from the *Mdm2* and *Mdm4* deletions in mice, the inhibitors targeting Mdm2 may cause lymphocyte and epithelial defects when the inhibition reduces Mdm2 efficacy to 30%; therefore, Mdm4 inhibitors in cancer patients may be a more desirable choice due to the fewer deleterious effects on normal tissues. Certainly, it will also be important to investigate whether the effects of *Mdm2* and *Mdm4* inhibition are age- and tumor type-dependent.

Mouse Models for the Tissue-specific Deletion of *Mdm2* and *Mdm4* {#s3}
==================================================================

To understand how Mdm2 and Mdm4 regulate p53 activity together in specific tissues or specific cell types, *Mdm2* and *Mdm4* conditional alleles have been generated[@b23],[@b24]. Tissue-specific *Mdm2* deletion in the heart, intestine, testis, thymus, spleen, erythrocytes, adult smooth muscle cells, bone, and hepatocytes induces *p53*-dependent apoptosis[@b25]--[@b27]. The effects of *Mdm4* deletion are more complex. *Mdm4* deletion in the quiescent or fully differentiated adult smooth muscle cells does not cause obvious defects[@b28]. On the other hand, although the loss of *Mdm4* in the embryonic heart does not cause any obvious defect, it induces apoptosis in cardiomyocytes and leads to dilated cardiomyopathy in adult mice, suggesting that non-proliferating cardiomyocytes also require Mdm4 to inhibit p53 [@b29]. These data suggest that the Mdm4 inhibition of p53 is not cell cycle-dependent but depends on the cell type or the endogenous levels of Mdm2 and p53. The deletion of both *Mdm2* and *Mdm4* induces higher p53 activity than the deletion of *Mdm2* alone in the embryonic central nervous system, indicating that Mdm2 and Mdm4 cooperatively inhibit p53. These data indicate that a combination therapy by employing both Mdm2 and Mdm4 inhibitors to induce p53 activity in tumors may activate p53 more strongly and therefore have a better treatment outcome [@b30].

Mouse Models of *Mdm2* and *Mdm4* Knockin {#s4}
=========================================

The relationship of Mdm2 and Mdm4 in regulating p53 is very complex. Both Mdm2 and Mdm4 bind to the p53 transactivation domain with similar affinities; therefore, they may compete for the binding and inhibition of p53 activity. Additionally, Mdm2 and Mdm4 interact with each other through their respective RING finger domains[@b31]. Mdm2 is also an E3 ubiquitin ligase of Mdm4[@b32]. To understand the role of the Mdm2-Mdm4 interaction in regulating p53 activity, two knockin mouse models, *Mdm4^C462A^* and *Mdm4^ΔRing^*, have been generated[@b33],[@b34]. The Mdm4^C462A^ *and* Mdm4^ΔRing^ proteins fail to bind to Mdm2, but both of them bind to p53 and are more stable than wild-type Mdm4. However, both mouse models show *p53*-dependent early embryonic lethality, indicating that Mdm2 and Mdm4 binding is essential for inhibiting p53 activity during embryogenesis. This implies that the Mdm2 and Mdm4 heterodimers may ubiquitinate p53 more efficiently than the Mdm2 homodimers. Interestingly, the p53 protein level and activity does not change in the adult tissues or mouse embryonic fibroblasts of *Mdm4^ΔRing^* when a hypomorphic *p53^neo^* allele is used to rescue the mice from early lethality, indicating that the interaction of Mdm2 and Mdm4 may not be important for normal tissues or during homeostatic conditions in later stages. Therefore, improving the interaction between Mdm2 and Mdm4 could be another strategy to activate p53 in cancer patients, but this needs to be further examined.

Mouse Models of *Mdm2* and *Mdm4* Overexpression {#s5}
================================================

*MDM2* and *MDM4* have been found to be overexpressed in many human cancers[@b35]--[@b39]. Overexpression of *Mdm2* in mice leads to tumorigenesis with a significantly higher percentage of sarcoma than the *p53* null mice, suggesting that *Mdm2* overexpression may have a *p53*-independent function[@b40]. There are two transgenic mouse models of *Mdm4*. One induced spontaneous tumors and accelerates tumorigenesis of *p53* heterozygosity in the mouse[@b41]. However, the other transgenic mouse model did not induce tumorigenesis within 50 weeks. When crossed with the *Eµ*-*myc* transgene, a p53 dosage-sensitive tumor model, it did not accelerate tumorigenesis[@b42]. Because the relative concentrations of Mdm2 and Mdm4 are important for their inhibitory effects on p53[@b43], the discrepancy may be due to different expression levels of Mdm4 in these two transgenic lines. These studies again demonstrate that Mdm2 and Mdm4 are critical negative regulators of p53. More importantly, they suggest that the overexpression of *Mdm2* and *Mdm4* is another mechanism for tumorigenesis in cancer patients. This strongly supports that blocking the inhibition of Mdm2 and Mdm4 with p53 can be a therapeutic strategy to treat cancer patients.

In summary, the mouse models of *Mdm2* and *Mdm4* have greatly improved and expanded our knowledge of their inhibitory function towards p53. They also clarify the conflicting results from different cell culture studies. Although the conclusions based on the loss of function mouse models of *Mdm2* and *Mdm4* were drawn from irreversible deletion, they still provide very valuable information for understanding the tissue specificity and sensitivity of Mdm2 or Mdm4 inhibition. The results from the mouse models strongly suggest localized treatment in cancer patients to avoid any unwanted damages could be caused by these inhibitors. Furthermore, mouse models with *Mdm2* or *Mdm4* overexpression demonstrate that these two genes are truly oncogenes that can drive spontaneous tumorigenesis in the presence of wild-type *p53* alleles, and this further supports the idea of treating cancer patients with high levels of these two proteins by the inhibitors. The mouse models of *Mdm2* and *Mdm4* overexpression can also be used to test the efficacy of the preclinical Mdm2 and Mdm4 inhibitors *in vivo*.
